



Lars F. Berglund, M.D., Ph.D.

Research/Academic Interests

Dr. Berglund oversees all aspects of the School of Medicine research portfolio, with responsibility for strategic planning, space assignments, matching and bridging funds, and representing the school at the institutional and national level. He works closely with center directors and department chairs in strategic recruitments and development of research initiatives.

Berglund also is emeritus director of the Clinical and Translational Science Center (CTSC), and was responsible for all of the center's infrastructure activities, including services, education and translational science projects. He serves as principal investigator for the health system's KL2 and TL1 training grant programs, which accelerate the career development of promising junior faculty and pre-doctoral students. Through these activities, he has mentored a wide range of trainees, including undergraduate and graduate students, fellows and junior faculty.

Berglund also serves as one of three principal investigators for the UC Davis FUTURE program, which is funded by a NIH Director's BEST award to develop novel career pathways for graduate students. He has participated in Clinical and Translational Science Award network activities and served as the inaugural co-chair of the CTSA Steering committee.

Berglund is a member of the editorial boards of several journals. He has chaired a NIH study section and a national American Heart Association study section, and has served on multiple NIH study sections and on committees for the American Heart Association, the Endocrine Society and a National Academies Steering Committee for the Decadal Survey on Biological and Physical Sciences in Space.

Title	Distinguished Professor Emeritus
Specialty	Internal Medicine
Department	Internal Medicine
Division	Endocrinology, Diabetes, and Metabolism
Center/Program Affiliation	Clinical and Translational Science Center UC Davis Comprehensive Cancer Center
Address/Phone	Clinical and Translational Science Center, 2921 Stockton Blvd. Suite 1400 Sacramento, CA 95817 Phone: 916-703-9184
Additional Phone	Phone: 800-4-UCDAVIS (800-482-3284)
Languages	Swedish



Lars F. Berglund, M.D., Ph.D.

Education	M.D., University of Uppsala, Uppsala, Sweden 1981 Ph.D., Biochemistry, University of Uppsala, Uppsala, Sweden 1977
Internships	Rotating (Surgery, Anesthesiology, Medicine, Psychiatry, General practice), Karolinska Institute, Stockholm, Sweden 1981-1982
Residency	Internal Medicine and Laboratory Medicine, Karolinska Institute, Stockholm, Sweden 1982-1984
Fellowships	Internal Medicine (Endocrinology and Metabolic Disease), UC San Diego, San Diego CA 1977-1979
Professional Memberships	American Heart Association Association for Clinical and Translational Science Endocrine Society
Honors and Awards	Dean's Award for Excellence in Research, UC Davis, 2014 Elected Fellow, American Association for the Advancement of Science (AAAS), 2013 JCE&M Outstanding Reviewer Recognition Award, 2007 Elected Fellow of the American Heart Association (FAHA), 1996 Established Scientist, American Heart Association, New York City Affiliate, 1994, 1995, 1996, 1997
Select Recent Publications	Reyes-Soffer G, Ginsberg HN, Berglund L, Duell PB, Heffron SP, Kamstrup PR, Lloyd-Jones DM, Marcovina SM, Yeang C, Koschinsky ML; American Heart Association Council on Arteriosclerosis, Thrombosis and Vascular Biology; Council on Cardiovascular Radiology and Intervention; and Council on Peripheral Vascular Disease. Lipoprotein(a): A Genetically Determined, Causal, and Prevalent Risk Factor for Atherosclerotic Cardiovascular Disease: A Scientific Statement From the American Heart Association. <i>Arterioscler Thromb Vasc Biol.</i> 2022 Jan;42(1):e48-e60. doi:10.1161/ATV.000000000000147. Epub 2021 Oct 14. PMID:34647487. Enkhmaa B, Berglund L. Lp(a) and SARS-CoV-2: A conspiracy of two mysteries. <i>J Intern Med.</i> 2022 Jan;291(1):8-10. doi:10.1111/joim.13356. Epub 2021 Oct 29. PMID:34713951. Berglund L, Kim K, Zhang W, Prakash N, Truax K, Anuurad E, Enkhmaa B. Lp(a)-Associated Oxidized Phospholipids in Healthy Black and White Participants in Relation to apo(a) Size, Age, and Family Structure. <i>J Am Heart Assoc.</i> 2021 Sep 7;10(17):e020158. doi:10.1161/JAHA.120.020158. Epub 2021 Aug 25. PMID:34431330.



Lars F. Berglund, M.D., Ph.D.

Guo BP, Rainwater J, Neves S, Anuurad E, Wun T, Berglund L. Building an institutional K awardee program at UC Davis through utilization of CTSA resources. *J Clin Transl Sci.* 2021 Aug 13;5(1):e171. doi:10.1017/cts.2021.839. PMID:34733547.

Enkhmaa B, Petersen KS, Kris-Etherton PM, Berglund L. Diet and Lp(a): Does Dietary Change Modify Residual Cardiovascular Risk Conferred by Lp(a)? *Nutrients.* 2020 Jul 7;12(7):2024. doi: 10.3390/nu12072024. PMID:32646066.

Enkhmaa B, Kim K, Zhang W, Prakash N, Truax K, Anuurad E, Berglund L. SUN-580 PCSK9 and Lp(a): Association Between PCSK9 Level and Larger Apo(a) Isoform Size in African-Americans and Caucasians. *J Endocrine Soc.* 2020 Apr-May 8;4(Sup 1):SUN-580. doi:10.1210/jendso/bvaa046. 1329.

Enkhmaa B, Anuurad E, Zhang W, Kim K, Berglund L. Heritability of apolipoprotein (a) traits in two-generational African-American and Caucasian families. *J Lipid Res.* 2019 Sep;60(9):1603-1609. doi:10.1194/jlr.P091249. Epub 2019 Jul 18. PMID:31324652.

Rosenzweig JL, Bakris GL, Berglund LF, Hivert MF, Horton ES, Kalyani RR, Murad MH, Vergès BL. Primary Prevention of ASCVD and T2DM in Patients at Metabolic Risk: An Endocrine Society* Clinical Practice Guideline. *J Clin Endocrinol Metab.* 2019 Jul 31;jc.2019-01338. doi:10.1210/jc.2019-01338. Epub ahead of print. PMID:31365087.

Anuurad E, Enkhmaa B, Gungor Z, Zhang W, Tracy RP, Pearson TA, Kim K, Berglund L. Age as a modulator of inflammatory cardiovascular risk factors. *Arterioscler Thromb Vasc Biol.* 2011 Sep;31(9):2151-6. doi:10.1161/ATVBAHA.111.232348. Epub 2011 Jun 23. PMID:21700927.

Stanhope KL, Griffen SC, Bremer AA, Vink RG, Schaefer EJ, Nakajima K, Schwarz JM, Beysen C,



Lars F. Berglund, M.D., Ph.D.

Berglund L, Keim NL, Havel PJ. Metabolic responses to prolonged consumption of glucose- and fructose-sweetened beverages are not associated with postprandial or 24-h glucose and insulin excursions. *Am J Clin Nutr*. 2011 Jul;94(1):112-9. doi:10.3945/ajcn.110.002246. Epub 2011 May 25. PMID:21613559.

© 2024 UC Regents